Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Darbepoetin alfa controversies, from dosage issues to safety concerns: the larger lesson.

Glaspy JA.

Oncology (Williston Park). 2011 Apr 30;25(5):423-4. No abstract available.

2.

Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.

Yang MC.

Ann Pharmacother. 2006 May;40(5):998-9; author reply 999. Epub 2006 May 2. No abstract available.

PMID:
16670351
3.

Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.

Gordon D, Nichols G, Ben-Jacob A, Tomita D, Lillie T, Miller C.

Oncologist. 2008 Jun;13(6):715-24. doi: 10.1634/theoncologist.2007-0241.

4.

Managing anemia in patients with chronic kidney disease or cancer: development and role of darbepoetin alfa.

Scott SD.

Pharmacotherapy. 2002 Sep;22(9 Pt 2):129S-132S. Review. No abstract available.

PMID:
12222582
5.

Erythropoietin: high profile, high scrutiny.

Crawford J.

J Clin Oncol. 2007 Mar 20;25(9):1021-3. Epub 2007 Feb 20. No abstract available.

PMID:
17312331
6.

Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia.

Bohlius J, Engert A, Schwarzer G.

JAMA. 2008 Dec 24;300(24):2854-5; author reply 2855-7. doi: 10.1001/jama.2008.868. No abstract available.

PMID:
19109112
7.

Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.

Charu V, Belani CP, Gill AN, Bhatt M, Tomita D, Rossi G, Ben-Jacob A.

Oncologist. 2007 Jun;12(6):727-37.

8.

[Development trend in new therapeutic approaches for anemia].

Ohyashiki K.

Nihon Rinsho. 2008 Mar;66(3):569-74. Review. Japanese.

PMID:
18326328
9.

Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.

[No authors listed]

Drug Ther Bull. 2004 Mar;42(3):21-3. Review.

PMID:
15038080
10.

Epoetin alfa and darbepoetin alfa go head to head.

Steensma DP, Loprinzi CL.

J Clin Oncol. 2006 May 20;24(15):2233-6. No abstract available.

PMID:
16710021
11.

Darbepoetin alfa and history of thromboembolic events.

Ferretti G, Felici A, Cognetti F.

J Clin Oncol. 2009 Nov 20;27(33):e211; author reply e212. doi: 10.1200/JCO.2009.24.6454. Epub 2009 Oct 26. No abstract available.

PMID:
19858373
12.

Development of a strategy to successfully convert an ambulatory infusion center from epoetin alfa to darbepoetin alfa.

Longfield V, Gebhart B, Hayward L.

J Support Oncol. 2005 Nov-Dec;3(6 Suppl 4):8-9. No abstract available.

PMID:
16355548
13.

Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.

Kelaidi C, Fenaux P.

Expert Opin Biol Ther. 2010 Apr;10(4):605-14. doi: 10.1517/14712591003709713. Review.

PMID:
20201708
14.

Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia.

Steensma DP, Sasu BJ, Sloan JA, Tomita DK, Loprinzi CL.

Blood. 2015 Jun 4;125(23):3669-71. doi: 10.1182/blood-2015-03-636407. Review. No abstract available.

PMID:
26045598
15.

Treatment of anemia with darbepoetin alfa in systolic heart failure.

Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees; RED-HF Investigators.

N Engl J Med. 2013 Mar 28;368(13):1210-9. doi: 10.1056/NEJMoa1214865. Epub 2013 Mar 10.

16.

An ongoing study of anemia correction in chronic kidney disease.

Pfeffer MA; TREAT Executive Committee.

N Engl J Med. 2007 Mar 1;356(9):959-61. No abstract available.

PMID:
17329707
17.

Anemia: To TREAT or not to TREAT--that is the question.

Wiecek A.

Nat Rev Nephrol. 2010 May;6(5):254-5. doi: 10.1038/nrneph.2010.35. No abstract available.

PMID:
20424627
18.

Does TREAT give the boot to ESAs in the treatment of CKD anemia?

Singh AK.

J Am Soc Nephrol. 2010 Jan;21(1):2-6. doi: 10.1681/ASN.2009111127. Epub 2009 Dec 24. No abstract available.

19.

Should all patients with chronic kidney disease receive an EPO-type drug?

Berns JS.

Cleve Clin J Med. 2006 Mar;73(3):298-300. No abstract available.

PMID:
16548453
20.

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators.

N Engl J Med. 2009 Nov 19;361(21):2019-32. doi: 10.1056/NEJMoa0907845. Epub 2009 Oct 30.

Supplemental Content

Support Center